Author: News Room
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Franklin To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Franklin between November 5, 2024 and February 11, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Franklin BSP Realty Trust, Inc. (“Franklin”…
CLEVELAND, March 13, 2026 (GLOBE NEWSWIRE) — SPR®, a leading private medical device company focused on improving the lives of millions of people living with pain, announced that Aetna has published an updated medical policy that designates the SPR SPRINT PNS System as medically necessary when used for intractable neuropathic pain and when Aetna’s selection criteria are met. This decision broadens access to an estimated 22.3 million covered lives across the United States. Under Aetna’s updated medical policy, the SPRINT PNS System is now considered a covered treatment option for appropriate patients who meet the policy’s criteria. The policy recognizes SPRINT PNS…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Helen of Troy To Contact Him Directly To Discuss Their Options If you suffered significant losses in Helen of Troy stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helen of Troy Limited (“Helen of Troy” or…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bath & Body Works To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bath & Body Works between June 4, 2024 and November 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bath…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Smart Digital To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Smart Digital between May 5, 2025 and September 26, 2025 at 9:34 AM EST and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Smart…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding In Navan To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Navan pursuant to the Offering Documents on October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Navan, Inc. (“Navan” or the…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (“Ultragenyx” or the “Company”)…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:…
Dublin, March 13, 2026 (GLOBE NEWSWIRE) — The “Subscription Billing Management Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035” has been added to ResearchAndMarkets.com’s offering. The subscription billing management market, valued at USD 8.47 billion in 2025, is set for robust growth, reaching an estimated USD 37.36 billion by 2035. This reflects a compound annual growth rate (CAGR) of 16% from 2026 to 2035, indicative of a global shift towards subscription-based business models and the related demand for robust billing infrastructure. Key to this expansion is the transition across industries to subscription and consumption-based monetization, which enables predictable revenue…